
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

ASKC202 + Limertinib vs Chemo in MET+ NSCLC After EGFR-TKI
Details : ASKC202 is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent’s Limertinib Approved By NMPA for First-Line Lung Cancer Treatment
Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI, approved by NMPA for the first-line treatment of adult patients with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent and ASK Pharm Announce NMPA Approval of Limertinib for Lung Cancer
Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI with proprietary rights, approved by NMPA for the treatment of adults with locally advanced or metastatic EGFR T790M-mutated NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Innovent And Ask Pharm Collaborate on Limertinib For Lung Cancer Treatment
Details : Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib, a third-generation EGFR inhibitor for the treatment of lung cancer, in mainland China.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKC200
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain
Details : ASKC200 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : ASKC200
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASKB589 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Junction Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG712 in Patients With Diabetic Macular Edema
Details : ASKG712 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG915
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Details : ASKG915 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 22, 2023
Lead Product(s) : ASKG915
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASKB589 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 01, 2022
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : AskGene Pharma Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifampicin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
Details : Rifampicin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Rifampicin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
